847 / 1609
APBI: 1.44%
WBI: 0.92%
No grade 4 late side-effects.
APBI WBI
5-year risk G2-3 late side-effects to the skin:
3.2% 5.7% (p=0.08)
5-year risk of G2–3 late subcutaneous tissue :
7.6% 6.3% (p=0.53)
Severe (G3) fibrosis at 5 years:
0 0.2% (p=0.46)
APBI using multicatheter brachytherapy can be regarded as a valid
alternative treatment option after breast-conserving surgery and can be
offered for all low-risk breast cancer patients in clinical routine.
APBI: 97%
WBI: 95%
Local recurrence
Overall survival
Strnad V et al.Lancet. 2016 Jan 16;387(10015):229-38